The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 726
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
McCloskey, C. W., Rodriguez, G. M., Galpin, K. J. C., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080244 · Cited by 64
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Cantini, L., Hassan, R., Sterman, D. H., & Aerts, J. G. J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00343 · Cited by 60
The Ugly Duckling Turned to Swan: A Change in Perception of Bystander-Activated Memory CD8 T Cells
Maurice, N. J., Taber, A. K., & Prlic, M. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000937 · Cited by 57
Jaiswal, A., Verma, A., Dannenfelser, R., Melssen, M. M., Tirosh, I., Izar, B., Kim, T., Nirschl, C. J., Devi, K. S. P., Olson, W. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.005 · Cited by 61
Kato, T., Matsuda, T., Ikeda, Y., Park, J.-H., Leisegang, M., Yoshimura, S., Hikichi, T., Harada, M., Zewde, M. G., Sato, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24232 · Cited by 58
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
Paul, S., Pearlman, A. H., Douglass, J., Mog, B. J., Hsiue, E. H.-C., Hwang, M. S., DiNapoli, S. R., Konig, M. F., Brown, P. A., Wright, K. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3595 · Cited by 60
Nojima, I., Eikawa, S., Tomonobu, N., Hada, Y., Kajitani, N., Teshigawara, S., Miyamoto, S., Tone, A., Uchida, H. A., Nakatsuka, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71946-3 · Cited by 58
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Markowitz, G. J., Havel, L. S., Crowley, M. J. P., Ban, Y., Lee, S. B., Thalappillil, J. S., Narula, N., Bhinder, B., Elemento, O., Wong, S. T. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96836 · Cited by 59
CAR T cells and checkpoint inhibition for the treatment of glioblastoma
Shen, S. H., Woroniecka, K. I., Barbour, A. B., Fecci, P. E., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1727436 · Cited by 62
Long-term antigen exposure irreversibly modifies metabolic requirements for T cell function
Bettonville, M., d'Aria, S., Weatherly, K., Porporato, P. E., Zhang, J., Bousbata, S., Sonveaux, P., & Braun, M. Y. (2018) · eLife · doi:10.7554/elife.30938 · Cited by 62
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 57
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 60
Knowns and Unknowns about CAR-T Cell Dysfunction
Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 56
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 66
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Im, S. J., & Ha, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e2 · Cited by 58
Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma
Kourtis, N., Wang, Q., Wang, B., Oswald, E. M., Adler, C., Cherravuru, S., Malahias, E., Zhang, L., Golubov, J., Wei, Q., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00391-0 · Cited by 55
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
Jindal, S., Pennock, N. D., Sun, D., Horton, W. R., Ozaki, M. K., Narasimhan, J., Bartlett, A. Q., Weinmann, S. A., Goss, P. E., Borges, V. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26505-3 · Cited by 55
Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation
Jiang, M., Gu, D.-N., Dai, J., Huang, Q., & Tian, L. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.018 · Cited by 54
Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion
Busselaar, J., Tian, S., van Eenennaam, H., & Borst, J. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592569 · Cited by 57
The lymphatic vasculature: An active and dynamic player in cancer progression
Rezzola, S., Sigmund, E. C., Halin, C., & Ronca, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21855 · Cited by 54
Boukhaled, G. M., Gadalla, R., Elsaesser, H. J., Abd-Rabbo, D., Quevedo, R., Yang, S. Y. C., Guo, M., Wang, B. X., Noamani, B., Gray, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01262-7 · Cited by 55
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Olson, K., Rizvi, S., Fiaschi, N., Coetzee, S., Wang, F., Ullman, E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1082 · Cited by 54
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer
Li, Y., Gu, Y., Yang, P., Wang, Y., Yu, X., Li, Y., Jin, Z., & Xu, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s439969 · Cited by 54
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 56
Current and upcoming mitochondrial targets for cancer therapy
Kim, H. K., Noh, Y. H., Nilius, B., Ko, K. S., Rhee, B. D., Kim, N., & Han, J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.006 · Cited by 52
Xiong, H., Mittman, S., Rodriguez, R., Pacheco-Sanchez, P., Москаленко, М., Yang, Y., Elstrott, J., Ritter, A. T., Müller, S., Nickles, D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0750 · Cited by 53
Use of Mass Cytometry to Profile Human T Cell Exhaustion
Winkler, F., & Bengsch, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03039 · Cited by 54
Egelston, C. A., Guo, W., Tan, J., Avalos, C., Simons, D. L., Lim, M. H., Huang, Y., Nelson, M. S., Chowdhury, A., Schmolze, D. B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153963 · Cited by 56
Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
Tien, F., Lu, H., Lin, S., & Tsai, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00893-0 · Cited by 51
Low-avidity T cells drive endogenous tumor immunity in mice and humans
Singhaviranon, S., Dempsey, J. P., Hagymasi, A. T., Măndoiu, I., & Srivastava, P. K. (2025) · Nature Immunology · doi:10.1038/s41590-024-02044-z · Cited by 53
The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders
Terrabuio, E., Zenaro, E., & Constantin, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1233870 · Cited by 51
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 52
Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
Jung, I.-Y., & Lee, J. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0242 · Cited by 49
Fischbeck, A. J., Rühland, S., Ettinger, A. W., Paetzold, K., Masouris, I., Noeßner, E., & Mendler, A. N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589434 · Cited by 49
Inflammatory signals are sufficient to elicit TOX expression in mouse and human CD8+ T cells
Maurice, N. J., Berner, J., Taber, A. K., Zehn, D., & Prlic, M. (2021) · JCI Insight · doi:10.1172/jci.insight.150744 · Cited by 47
Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45
Frisch, A. T., Wang, Y., Xie, B., Yang, A., Ford, B. R., Joshi, S. K., Kedziora, K. M., Peralta, R. M., Wilfahrt, D. N., Mullett, S. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.007 · Cited by 50
Transcriptional and epigenetic regulation of T cell hyporesponsiveness
Pereira, R. M., Hogan, P. G., Rao, A., & Martínez, G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ri0317-097r · Cited by 50
Kiryu, S., Ito, Z., Suka, M., Bito, T., Kan, S., Uchiyama, K., Saruta, M., Hata, T., Takano, Y., Fujioka, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08911-4 · Cited by 44
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Pan, Y., Shu, G., Fu, L., Huang, K., Zhou, X., Gui, C., Liu, H., Jin, X., Chen, M., Li, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202206792 · Cited by 47
Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy
Nüssing, S., Trapani, J. A., & Parish, I. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589641 · Cited by 48
Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Tabana, Y., Moon, T. C., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937123 · Cited by 47
Hua, L., Yang, Z., Li, W., Zhang, Q., Ren, Z., Ye, C., Zheng, X. W., Li, D., Long, Q., Bai, H., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103923 · Cited by 45
Cai, T., Gouble, A., Black, K. L., Skwarska, A., Naqvi, A. S., Taylor, D. M., Zhao, M., Yuan, Q., Sugita, M., Zhang, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29669-8 · Cited by 49
Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy
Castro-Sanchez, P., Teagle, A. R., Prade, S., & Zamoyska, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608747 · Cited by 44
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 45
Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells
Salerno, F., Guislain, A., Heeren, J. J. F., Nicolet, B. P., Young, H. A., & Wolkers, M. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532762 · Cited by 45
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
Peters, F. S., Strefford, J. C., Eldering, E., & Kater, A. P. (2021) · Haematologica · doi:10.3324/haematol.2020.267914 · Cited by 43
Umbilical cord blood: A promising source for allogeneic CAR-T cells
Liu, D.-D., Hong, W., Qiu, K., Li, X., Liu, Y., Zhu, L., Lai, W.-X., Chen, H., Yang, H., Xu, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944248 · Cited by 43
Kaptein, P., Slingerland, N., Metoikidou, C., Prinz, F., Brokamp, S., Machuca-Ostos, M., de Roo, G., Schumacher, T. N., Yeung, Y. A., Moynihan, K. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1263 · Cited by 41
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49
Thangam, R., Patel, K. D., Kang, H., & Paulmurugan, R. (2021) · Vaccines · doi:10.3390/vaccines9080935 · Cited by 44
Fernandes, Â., Azevedo, C. M., Silva, M. C., Faria, G., Dantas, C. S., Vicente, M. M., & Pinho, S. S. (2022) · Immunology · doi:10.1111/imm.13494 · Cited by 42
Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis
Bi, Q., Wu, J., Qiu, X., Zhang, J., Sun, Z., & Wang, W. (2022) · Journal of Immunology Research · doi:10.1155/2022/3128933 · Cited by 47
Han, J. W., & Yoon, S. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091387 · Cited by 40
Epigenetics and CD8+ T cell memory*
Montacchiesi, G., & Pace, L. (2021) · Immunological Reviews · doi:10.1111/imr.13057 · Cited by 43
Alexander, M. R., Dale, B. L., Smart, C. D., Elijovich, F., Wogsland, C. E., Lima, S. M., Irish, J. M., & Madhur, M. S. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.09.007 · Cited by 42
Tracy, S. I., Venkatesh, H., Hekim, C., Heltemes-Harris, L. M., Knutson, T. P., Bachanová, V., & Farrar, M. A. (2022) · Blood · doi:10.1182/blood.2021015341 · Cited by 41
Tee, S. S., Kim, N., Cullen, Q., Eskandari, R., Mamakhanyan, A., Srouji, R. M., Chirayil, R., Jeong, S., Shakiba, M., Kastenhuber, E. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm7985 · Cited by 39
Self-citationAnderson, K. G., Voillet, V., Bates, B. M., Chiu, E. Y., Burnett, M. G., Garcia, N. M., Oda, S. K., Morse, C. B., Stromnes, I. M., Drescher, C. W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0258 · Cited by 40
Self-citationLith, S. C., van Os, B. W., Seijkens, T. T. P., & de Vries, C. J. M. (2020) · European Journal of Immunology · doi:10.1002/eji.202048869 · Cited by 39
Hansen, K., Kumar, S., Logronio, K. A., Whelan, S., Qurashi, S., Cheng, H., Drake, A., Tang, M. L., Wall, P., Bernados, D., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02921-8 · Cited by 39
Advancing beyond the twists and turns of T cell exhaustion in cancer
van der Heide, V., Humblin, É., Vaidya, A. B., & Kamphorst, A. O. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4997 · Cited by 41
Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells
Nah, J., & Seong, R. H. (2022) · Science Advances · doi:10.1126/sciadv.adc9346 · Cited by 40
Lou, Z., Zhang, Y., Liang, X., Cao, M., Ma, Y., Chen, P. R., & Fan, X. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17879 · Cited by 42
Abken, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.115 · Cited by 39
Sawada, M., Goto, K., Morimoto-Okazawa, A., Haruna, M., Yamamoto, K., Yamamoto, Y., Nakagawa, S., Hiramatsu, K., Matsuzaki, S., Kobayashi, E., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa010 · Cited by 41
Spatial determinants of CD8+ T cell differentiation in cancer
Tooley, K., Escobar, G., & Anderson, A. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.003 · Cited by 38
Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma
Sui, Z., Wu, X., Du, L., Wang, H., Yuan, L., Zhang, J. V., & Yu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879326 · Cited by 38
T cell senescence: a new perspective on immunotherapy in lung cancer
Huang, M., Wang, Y., Fang, L., Liu, C., Feng, F., Liu, L., & Sun, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1338680 · Cited by 37
A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunity
Gao, Q., Feng, L., Wang, S., Shen, Z., Cheng, S., Ping, Y., Qin, G., Chen, X., Li, Y., Cao, L., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.08.011 · Cited by 37
Mouse Models for Immunotherapy in Hepatocellular Carcinoma
Li, E., Lin, L., Chen, C., & Ou, D. (2019) · Cancers · doi:10.3390/cancers11111800 · Cited by 39
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Wijewarnasuriya, D., Bebernitz, C., Lopez, A. V., Rafiq, S., & Brentjens, R. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0908 · Cited by 38
Toward “off‐the‐shelf” allogeneic CAR T cells
Aftab, B. T., Sasu, B. J., Krishnamurthy, J., Gschweng, E. H., Alcazer, V., & Depil, S. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.86 · Cited by 40
Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy
Wan, C., Sun, Y., Hu, Y., Huang, J., Lu, L., Gao, Y., Zi, H., He, Q., Sun, J., Lovell, J. F., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101323 · Cited by 37
Cyclic nucleotide phosphodiesterases as drug targets
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Heßlinger, C., Nickolaus, P., Kass, D. A., de Vasconcelos, W. P., Fischmeister, R., Brocke, S., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100042 · Cited by 38
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 37
Liu, L., Chang, Y., Xu, L., Zhang, X., Wang, Y., Liu, K., & Huang, X. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.009 · Cited by 36
Cheng, J., Xiao, Y., Peng, T., Zhang, Z., Qin, Y., Wang, Y., Shi, J., Yan, J., Zhao, Z., He, Z., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00892-0 · Cited by 37
Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 38
HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct
Evans, A. M., Salnikov, M. Y., Gameiro, S. F., Vareki, S. M., & Mymryk, J. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164825 · Cited by 37
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Pich-Bavastro, C., Yerly, L., Domizio, J. D., Tissot-Renaud, S., Gilliet, M. F., & Kuonen, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0219 · Cited by 35
PD-1 blockade prevents the progression of oral carcinogenesis
Dong, Y., Wang, Z., Mao, F., Cai, L., Dan, H., Jiang, L., Zeng, X. Y., Li, T., Zhou, Y. J., & Chen, Q. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab035 · Cited by 34
Qin, H., Ishii, K., Nguyen, S. M., Su, P. P., Burk, C. R., Kim, B., Duncan, B. B., Tarun, S., Shah, N. N., Kohler, M. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-815548 · Cited by 33
Nelson, C. E., Thompson, E. A., Quarnstrom, C. F., Fraser, K. A., Seelig, D. M., Bhela, S., Burbach, B. J., Masopust, D., & Vezys, V. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.038 · Cited by 31
Contribution of Macrophages and T Cells in Skeletal Metastasis
Mendoza‐Reinoso, V., McCauley, L. K., & Fournier, P. G. J. (2020) · Cancers · doi:10.3390/cancers12041014 · Cited by 35
Mitochondria as Playmakers of CAR T-cell Fate and Longevity
Rostamian, H., Khakpoor-Koosheh, M., Fallah-Mehrjardi, K., Mirzaei, H. R., & Brown, C. E. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0110 · Cited by 34
Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy
Li, W., Zhou, Y., Wu, Z., Shi, Y., Tian, E., Zhu, Y., Wang, T., Dou, W., Meng, X., Chen, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724306 · Cited by 33
Lewis, E. L., Xu, R., Beltra, J., Ngiow, S. F., Cohen, J. B., Telange, R., Crane, A., Sawinski, D. L., Wherry, E. J., & Porrett, P. M. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201599 · Cited by 32
Biomechanics of T Cell Dysfunctions in Chronic Diseases
Gunasinghe, S. D., Peres, N. G., Goyette, J., & Gaus, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.600829 · Cited by 33
Yang, Y., Liu, F., Liu, W., Ma, M., Gao, J., Lu, Y., Huang, L., Li, X., Shi, Y., Wang, X., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.133 · Cited by 31
Applications of Single-Cell Omics to Dissect Tumor Microenvironment
Guo, T., Li, W., & Cai, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.548719 · Cited by 33
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
Fitzgerald, B., Connolly, K. A., Cui, C., Fagerberg, E., Mariuzza, D. L., Hornick, N. I., Foster, G. G., William, I., Cheung, J. F., & Joshi, N. S. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100080 · Cited by 34
Epigenetic regulation of T cell exhaustion in cancer
Kang, T. G., Johnson, J. T., Zebley, C. C., & Youngblood, B. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00883-y · Cited by 36
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
